Abbvie Inc (ABBV)

$217.49 +4.37 (2.05%)
Market Cap 376.83B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 20.94
Forward PE 14.35
Profit Margin 6.91%
Debt to Equity Ratio -20.91
Volume 8,311,600
Avg Vol 7,331,508
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 90%
Beta 0.34
Analysts Strong Sell
Price Target $249.82

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
green_going_up
green_going_up Apr. 1 at 3:50 AM
$CLGN Aesthetic Wellness is one of the fastest growing markets; this firm has a development deal with $ABBV yet can't get any interest; reminds me of $LCTX which has a development deal with $RHHBY for GA; these firms get tiny milestone payments and just sit there waiting, hoping, and praying for these big firms to fully commit. They can take YEARS. And, you wonder if firm's like Abbvie and Roche don't just play the long game on purpose, eventually being able to pick up these micro-cap firm assets on the cheap once either these firms file for bankruptcy or dilute themselves so much because the shorts / naked shorts just pound them relentless until they are forced to de-list. Firms like these micro-cap ones MUST have really strong CFO's to raise way more than what's needed - Years Worth of Cash - in the period right after the initial partnership announcement spike. Otherwise, surviving the waiting game is a serious challenge.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 31 at 11:17 PM
$ABBV Share Price: $217.43 Contract Selected: Apr 24, 2026 $215 Calls Buy Zone: $5.78 – $7.14 Target Zone: $10.60 – $12.96 Potential Upside: 73% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Guntz
Guntz Mar. 31 at 7:47 PM
$ABBV Bust $220 soon and $230 comes quick
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Mar. 31 at 7:22 PM
$SLS @ezimon most don't realize how big the VERONA Failure is... - no Improvement in Overall Survival for High RISK MDS which is basically AML. - partly why $ABBV shut. down the VIALE-M trial for AML FIRST REMISSION Maintenance - there was no OS Benefit. - and there is No OS Benefit for the. SLS REGAL Control Patients - Just like Dr. Tsirigotis, Dr. Jamy and Dr. Levy have all Also, Stated on the Record. -- only the Truly DumbasF idiots can't understand - its GPS - Gps is the Only Reason we are seeing MIRACULOUS ALL Pooled Survival in the REGAL P3 Patients.
0 · Reply
Guntz
Guntz Mar. 31 at 5:20 PM
$ABBV Noooo markets don't leave us behind 😭
0 · Reply
OptionSamurai
OptionSamurai Mar. 31 at 2:53 PM
$ABBV appears in our scan that looks for calls that will explode if the stock goes to analyst target. Analysts rating is BUY and the target price is 17.8% away📈. Call 230.0, 18-Jun-26 has: Max loss of 3.5% compared to holding shares and Breakeven is 9.6% away. If the stock hits the target, the call will profit 235% 🔥🔥🔥. 👉 Create your own scan here: https://bit.ly/3lR1xIP
0 · Reply
Guntz
Guntz Mar. 31 at 2:37 PM
$ABBV $219 a big supply zone. Tough nut to crack
0 · Reply
Guntz
Guntz Mar. 31 at 2:20 PM
$ABBV Maybe too much too fast.
0 · Reply
GrapeGatsby
GrapeGatsby Mar. 31 at 2:03 PM
$ABBV Might find resistance at 220 end of gap fill and previous support.
0 · Reply
Guntz
Guntz Mar. 31 at 2:02 PM
$ABBV Let's fucking go!
0 · Reply
Latest News on ABBV
Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:05 AM EDT - 19 hours ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 31, 2026, 8:00 AM EDT - 19 hours ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

AbbVie: Strong 2026 Outlook, Expect Dividend Increases

Mar 27, 2026, 2:42 PM EDT - 4 days ago

AbbVie: Strong 2026 Outlook, Expect Dividend Increases

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 27, 2026, 10:00 AM EDT - 4 days ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 24, 2026, 8:00 AM EDT - 7 days ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

Mar 20, 2026, 12:11 PM EDT - 11 days ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 12 days ago

Buy Or Fear AbbVie Stock At $210?

Best Dividend Kings: March 2026

Mar 19, 2026, 3:27 AM EDT - 13 days ago

Best Dividend Kings: March 2026

ABM ABT ADM ADP AWR BDX BKH

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 19, 2026, 3:00 AM EDT - 13 days ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 13 days ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 14 days ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 13, 2026, 9:00 AM EDT - 18 days ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Harbor Health Care ETF Q4 2025 Portfolio Review

Mar 11, 2026, 8:18 AM EDT - 20 days ago

Harbor Health Care ETF Q4 2025 Portfolio Review

ABVX GMAB LLY MASI MEDI MRK RVMD

AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 10, 2026, 2:10 PM EDT - 21 days ago

AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 22 days ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 4, 2026, 2:02 AM EST - 4 weeks ago

AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript

February Dividends With 4 Raises: 1.6% Up To 14.5%

Mar 3, 2026, 8:14 AM EST - 4 weeks ago

February Dividends With 4 Raises: 1.6% Up To 14.5%

BMY BTI MA

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 3, 2026, 8:00 AM EST - 4 weeks ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Mar 2, 2026, 8:30 AM EST - 4 weeks ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

The High Dividend Yield Bull Market: 3 Compelling 6% Yields

Mar 2, 2026, 4:51 AM EST - 4 weeks ago

The High Dividend Yield Bull Market: 3 Compelling 6% Yields

AMGN AVGO BTI DIV ENB GTY JPM

Best Dividend Aristocrats For March 2026

Feb 27, 2026, 12:21 PM EST - 4 weeks ago

Best Dividend Aristocrats For March 2026

ABT ADM ADP AFL ALB AMCR AOS

Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie

Feb 26, 2026, 7:30 AM EST - 4 weeks ago

Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie

MRK

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 5 weeks ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23, 2026, 12:03 PM EST - 5 weeks ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Feb 23, 2026, 11:00 AM EST - 5 weeks ago

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Feb 20, 2026, 2:00 AM EST - 5 weeks ago

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

AbbVie Declares Quarterly Dividend

Feb 19, 2026, 9:37 AM EST - 5 weeks ago

AbbVie Declares Quarterly Dividend

AbbVie: Dominating Immunology While Building Oncology Upside

Feb 17, 2026, 1:11 AM EST - 6 weeks ago

AbbVie: Dominating Immunology While Building Oncology Upside

AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

Feb 13, 2026, 12:57 PM EST - 6 weeks ago

AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

54 Stocks, 9 Megatrends: My Favorite Places To Be While Capital Is 'Forced'

Feb 12, 2026, 7:30 AM EST - 6 weeks ago

54 Stocks, 9 Megatrends: My Favorite Places To Be While Capital Is 'Forced'

AM APH AR ASML AVAV BTU CARR

AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 6:49 PM EST - 6 weeks ago

AbbVie sues US health agency over Botox price controls

Abbvie sues US health agency over Botox

Feb 11, 2026, 5:13 PM EST - 6 weeks ago

Abbvie sues US health agency over Botox

2 Urgent Sells And 2 No Brainer Dividend Buys

Feb 11, 2026, 4:06 PM EST - 6 weeks ago

2 Urgent Sells And 2 No Brainer Dividend Buys

AEP AMGN BMY ESS HASI HD PFE

Dividend Kings: No Ideal Buys In February's 57

Feb 10, 2026, 9:45 AM EST - 7 weeks ago

Dividend Kings: No Ideal Buys In February's 57

ABM ADP CWT FRT FTS HRL HTO

AbbVie: The Market Is Getting It Wrong

Feb 5, 2026, 8:52 AM EST - 7 weeks ago

AbbVie: The Market Is Getting It Wrong

AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot

Feb 5, 2026, 4:25 AM EST - 7 weeks ago

AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot

AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise

Feb 4, 2026, 6:04 PM EST - 7 weeks ago

AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise

AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake

Feb 4, 2026, 5:45 PM EST - 7 weeks ago

AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake

AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)

Feb 4, 2026, 3:39 PM EST - 7 weeks ago

AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)

AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript

Feb 4, 2026, 1:20 PM EST - 7 weeks ago

AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

Feb 4, 2026, 12:38 PM EST - 7 weeks ago

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

AbbVie Revenue Rises on Immunology Growth

Feb 4, 2026, 8:34 AM EST - 7 weeks ago

AbbVie Revenue Rises on Immunology Growth

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

Feb 4, 2026, 8:18 AM EST - 7 weeks ago

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

Feb 4, 2026, 7:51 AM EST - 7 weeks ago

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Feb 4, 2026, 7:48 AM EST - 7 weeks ago

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

Feb 3, 2026, 8:50 AM EST - 2 months ago

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

Feb 3, 2026, 8:00 AM EST - 2 months ago

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

Jan 29, 2026, 10:30 PM EST - 2 months ago

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

ABVX CVLT FIX FTAI GKOS GMAB HLI

10 Highest Rated Dividend Kings For Generations Of Income

Jan 29, 2026, 10:10 AM EST - 2 months ago

10 Highest Rated Dividend Kings For Generations Of Income

ABM ABT ADM BDX BKH KMB KO

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

Jan 29, 2026, 8:00 AM EST - 2 months ago

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

green_going_up
green_going_up Apr. 1 at 3:50 AM
$CLGN Aesthetic Wellness is one of the fastest growing markets; this firm has a development deal with $ABBV yet can't get any interest; reminds me of $LCTX which has a development deal with $RHHBY for GA; these firms get tiny milestone payments and just sit there waiting, hoping, and praying for these big firms to fully commit. They can take YEARS. And, you wonder if firm's like Abbvie and Roche don't just play the long game on purpose, eventually being able to pick up these micro-cap firm assets on the cheap once either these firms file for bankruptcy or dilute themselves so much because the shorts / naked shorts just pound them relentless until they are forced to de-list. Firms like these micro-cap ones MUST have really strong CFO's to raise way more than what's needed - Years Worth of Cash - in the period right after the initial partnership announcement spike. Otherwise, surviving the waiting game is a serious challenge.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 31 at 11:17 PM
$ABBV Share Price: $217.43 Contract Selected: Apr 24, 2026 $215 Calls Buy Zone: $5.78 – $7.14 Target Zone: $10.60 – $12.96 Potential Upside: 73% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Guntz
Guntz Mar. 31 at 7:47 PM
$ABBV Bust $220 soon and $230 comes quick
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Mar. 31 at 7:22 PM
$SLS @ezimon most don't realize how big the VERONA Failure is... - no Improvement in Overall Survival for High RISK MDS which is basically AML. - partly why $ABBV shut. down the VIALE-M trial for AML FIRST REMISSION Maintenance - there was no OS Benefit. - and there is No OS Benefit for the. SLS REGAL Control Patients - Just like Dr. Tsirigotis, Dr. Jamy and Dr. Levy have all Also, Stated on the Record. -- only the Truly DumbasF idiots can't understand - its GPS - Gps is the Only Reason we are seeing MIRACULOUS ALL Pooled Survival in the REGAL P3 Patients.
0 · Reply
Guntz
Guntz Mar. 31 at 5:20 PM
$ABBV Noooo markets don't leave us behind 😭
0 · Reply
OptionSamurai
OptionSamurai Mar. 31 at 2:53 PM
$ABBV appears in our scan that looks for calls that will explode if the stock goes to analyst target. Analysts rating is BUY and the target price is 17.8% away📈. Call 230.0, 18-Jun-26 has: Max loss of 3.5% compared to holding shares and Breakeven is 9.6% away. If the stock hits the target, the call will profit 235% 🔥🔥🔥. 👉 Create your own scan here: https://bit.ly/3lR1xIP
0 · Reply
Guntz
Guntz Mar. 31 at 2:37 PM
$ABBV $219 a big supply zone. Tough nut to crack
0 · Reply
Guntz
Guntz Mar. 31 at 2:20 PM
$ABBV Maybe too much too fast.
0 · Reply
GrapeGatsby
GrapeGatsby Mar. 31 at 2:03 PM
$ABBV Might find resistance at 220 end of gap fill and previous support.
0 · Reply
Guntz
Guntz Mar. 31 at 2:02 PM
$ABBV Let's fucking go!
0 · Reply
GrapeGatsby
GrapeGatsby Mar. 31 at 2:02 PM
$ABBV Damn nice momentum congrats bulls.
0 · Reply
Guntz
Guntz Mar. 31 at 1:32 PM
$ABBV Here we go. The battle at $215
0 · Reply
Guntz
Guntz Mar. 31 at 12:31 PM
$ABBV Super bullish if it gets above $215 which is the 200ma but could see rotation out if markets are risk on.
0 · Reply
Lowkeyoptions
Lowkeyoptions Mar. 30 at 8:42 PM
$BFRG Based on 2024–2025 revenue data, the top pharmaceutical companies are dominated by Pfizer, Merck & Co., Johnson & Johnson, AbbVie, and Roche. These companies lead in manufacturing vaccines, oncology drugs, and innovative therapies, with several, particularly Pfizer, rebounding from lower COVID-19 product demand. Top 5 Pharmaceutical Companies (by 2024/2025 Revenue): $PFE Often leads by revenue due to COVID-19 vaccines and vaccines like Prevnar, though facing pressure to diversify. $MERCK (USA): Known for cancer immunotherapy Keytruda, which has driven significant growth, placing them high in the rankings. $JNJ Johnson & Johnson (USA): A diversified healthcare leader with strong positions in pharmaceuticals and medical $ABBV (USA): Known for immunology treatments like Humira, maintaining a top spot despite patent challenges. $RHHBY Roche (Switzerland): A leader in oncology and diagnostics, often ranking top five due to its specialized, high-cost therapies.
0 · Reply
Guntz
Guntz Mar. 30 at 6:13 PM
$ABBV Please no EOD sell off🙏
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Mar. 30 at 5:58 PM
$SLS =/+/- 60 Events just from the Control Arm WHILE we Await 80. Shorts Selling the Price down on a Short Con - offering the investment Opportunity of a Lifetime. MARK THIS POST. BAT / aka Aza+VEN - recently FAILED 3 Large and Expensive Phase 3 Trials conducted by $ABBV - including FAILING 2 For AML REMISSION MAINTENANCE. Aza+VEN Also FAILED the REGAL Phase 3 Control Arm Patients -- now you know. Just Realize, Gps IS absolutely Golden, Getting FDA Approval and worth $40B to Big Pharma, and act accordingly.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 30 at 5:51 PM
$ABBV one of the few absorbing the painful market gyrations.
0 · Reply
middleman
middleman Mar. 30 at 5:42 PM
$ABBV 🙌
0 · Reply
Guntz
Guntz Mar. 30 at 3:19 PM
$ABBV Would love for it to push through here and start testing the 200ma at $215
0 · Reply
DanaHiggenbotham181
DanaHiggenbotham181 Mar. 30 at 3:19 PM
@DanaHiggenbotham181 $ABBV Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD)
0 · Reply
Guntz
Guntz Mar. 30 at 1:54 PM
$ABBV This is a tough area to break through.
0 · Reply
Creator_SPY
Creator_SPY Mar. 30 at 10:23 AM
$ABBV between zones
0 · Reply